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Synopsis
HEY1 (hairy/enhancer-of-split related with YRPW motif 1) is a member of the basic helix–loop–helix-orange
(bHLH-O) family of transcription repressors that mediate Notch signalling. HEY1 acts as a positive regulator of the
tumour suppressor p53 via still unknown mechanisms. A MALDI-TOF/TOF MS analysis has uncovered a novel HEY1
regulatory phosphorylation event at Ser-68. Strikingly, this single phosphorylation event controls HEY1 stability and
function: simulation of HEY1 Ser-68 phosphorylation increases HEY1 protein stability but inhibits its ability to enhance
p53 transcriptional activity. Unlike wild-type HEY1, expression of the phosphomimetic mutant HEY1-S68D failed to
induce p53-dependent cell cycle arrest and it did not sensitize U2OS cells to p53-activating chemotherapeutic drugs.
We have identified two related kinases, STK38 (serine/threonine kinase 38) and STK38L (serine/threonine kinase
38 like), which interact with and phosphorylate HEY1 at Ser-68. HEY1 is phosphorylated at Ser-68 during mitosis and
it accumulates in the centrosomes of mitotic cells, suggesting a possible integration of HEY1-dependent signalling
in centrosome function. Moreover, HEY1 interacts with a subset of p53-activating ribosomal proteins. Ribosomal
stress causes HEY1 relocalization from the nucleoplasm to perinucleolar structures termed nucleolar caps. HEY1
interacts physically with at least one of the ribosomal proteins, RPL11, and both proteins cooperate in the inhibition of
MDM2-mediated p53 degradation resulting in a synergistic positive effect on p53 transcriptional activity. HEY1 itself
also interacts directly with MDM2 and it is subjected to MDM2-mediated degradation. Simulation of HEY1 Ser-68
phosphorylation prevents its interaction with p53, RPL11 and MDM2 and abolishes HEY1 migration to nucleolar caps
upon ribosomal stress. Our findings uncover a novel mechanism for cross-talk between Notch signalling and nucleolar
stress.
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INTRODUCTION
Hairy/enhancer-of-split related with YRPW motif proteins are
a family of transcription factors that belong to the vertebrate
basic-helix–loop–helix-orange (bHLH-O) family of transcrip-
tional repressors [1]. There are three HEY proteins; HEY1, HEY2
and HEYL, which are encoded by three distinct genes. HEY1, like
other members of the family, mediates Notch signalling. Upon
Notch pathway activation, HEY1 expression increases and it ac-
cumulates in the nucleus, leading to transcriptional inhibition of
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downstream targets. Thus, HEY1 is a critical effector within the
Notch signalling pathway during embryonic development [2].
In addition to its roles during embryogenesis, HEY1 has also
been linked to several cancer-related pathways. HEY1 is a direct
target gene of transforming growth factor β (TGF-β)/Smad sig-
nalling and HEY1 expression is essential for TGF-β-dependent
epithelial-to-mesenchymal transition, a developmental program
of cell plasticity frequently observed in advanced carcinogen-
esis [3]. The retinoblastoma (pRb)/E2F cell-cycle pathway can
up-regulate HEY1 expression in human glioma cells through E2F-
binding sites present in its promoter [4], and HEY1 expression
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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can also be induced by activation of the proto-oncogene c-Jun [5].
HEY1 has recently gained relevance to cancer because it has been
shown that it is a positive regulator of the p53 tumour suppressor
protein (TP53 or p53), a transcription factor key in cancer protec-
tion that regulates the expression of stress response genes, which
in turn prevent damaged cells to initiate malignant growth. There-
fore, TP53 is the most frequently mutated tumour suppressor in
human cancers [6]. HEY1 expression activates p53 and induces
apoptosis in vivo in different biological models and it was pro-
posed that these effects occur through transcriptional repression
of MDM2, a p53-specific E3 ubiquitin ligase that targets p53
to proteasome for degradation [7]. In addition, HEY1 expres-
sion results in p53-dependent growth arrest in Ewing sarcoma
family cancer cell lines [8]. Lastly, our laboratory demonstrated
that HEY1-dependent activation of p53 blocks cell proliferation
in human osteosarcoma cells (U2OS) and confers sensitivity to
p53-activating cancer drugs [9]. Therefore, there is a clear con-
tribution of HEY1 to the activation of p53, which elicits different
biological responses depending on the cellular context, although
little is known about the molecular mechanisms that underlie
this functional interaction. Moreover, alterations in the normal
function of HEY1-dependent pathways could affect p53 tumour
suppression function, contributing to cancer development.
To further understand the role of HEY1 in p53 signalling we
carried out a proteomic approach combining immunoprecipita-
tion with liquid chromatography coupled to tandem mass spectro-
metry, designed to uncover the functional interactions of HEY1
with cellular proteins and the post-translational modifications
present in those proteins. Here we describe a critical regulatory
phosphorylation event at HEY1 Ser-68 residue that modulates
its function as activator of p53 transcriptional activity. Detailed
studies carried out with phosphomimetic aspartic acid substitu-
tions or unphosphorylatable alanine substitutions at HEY1 Ser-
68 residue revealed the effects that simulation of HEY1 Ser-68
phosphorylation have in its stability and function. In addition we
have identified two related kinases, STK38 (NDR1) and STK38L
(NDR2), which interact with and phosphorylate HEY1 at Ser-68
residue and could have a previously unknown role in the reg-
ulation of its function. We also present evidence for a possible
novel role of HEY1 in the mediation and/or modulation of the
ribosomal protein (RP)/MDM2/p53 axis, responsible for the ac-
tivation of p53 upon nucleolar stress.
MATERIALS AND METHODS
Plasmids
The following plasmids have been described: pSG5-HEY1, GST-
HEY1 (full-length and deletion mutants Y, amino acids 1–
285; Y + O, amino acids 1–115; Y + O + H, amino acids
1–49; HLH, amino acids 116–299), pSG5-HEY2 [10], PIG3-
LUC and pCDNA-p53 [9], pSG5-HEYL [11], pCMV-MDM2
[12]. The complete open reading frame of human RPL11 was
amplified by PCR from pcDNA-myc3-L11 [13] and subcloned
into pSG5-Flag [10]. The complete open reading frame of human
NONO was amplified by PCR from cDNA obtained from human
U2OS cells and subcloned into pSG5-Flag. pSG5-HEY1-S68D,
pSG5-HEY1-S68A, pSG5-HEY1-S246D, pSG5-HEY1-S246A,
GST-HEY1-S68D and GST-HEY1-S68A were generated by PCR
site-directed mutagenesis.
Cell culture and transient transfections
U2OS [14] and H1299 [15] cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10 % fetal bovine
serum. Both cell lines were generous gift from Dr Susana Llanos
(Spanish National Cancer Research Center, CNIO). Twenty-four
hours before transfection, cells were plated in 24-well plates
(50000 cells per well), 60-mm dishes (500000 cells per dish) or
150-mm dishes (3500000 cells per dish). Cells were transfec-
ted using Lipofectamine LTX (Life Technologies). Transfected
plasmids are detailed in the figure legends. pRL-TK (10 ng/well,
Promega) was used as internal control for transfection efficiency
in luciferase assays. Cell extracts were assayed for luciferase
activity as described previously [10] or lysed to obtain whole cell
extracts.
Generation of U2OS polyclonal cell pools
expressing tetracycline-inducible HEY1 or
HEY1-S68D.
Lentiviral vectors encoding V5-tagged HEY1 or HEY1-S68D
were used to generate lentivirus expressing HEY1 or HEY1-
S68D by the ViraPowerTM T-RExTM system following man-
ufacturer’s instructions (Invitrogen). Cells were co-transduced
with Tet-repressor-lentivirus and either HEY1- or HEY1-S68D-
lentivirus. Selection of stably co-transduced cells was achieved
with Zeocin (1000 μg/ml) and Blasticidin (4 μg/ml). To induce
HEY1 or HEY1-S68D expression 1 μg/ml of tetracycline was
added to the media.
Proliferation assays
U2OS cells expressing tetracycline-inducible HEY1 or HEY1-
S68D were plated into 96-well plates (2500 cells/well). After
24 h 1 μg/ml of tetracycline was added and cell proliferation was
measured at different time points. Medium and tetracycline were
replaced every 3 days. Cell growth was determined in quadrup-
licates using the CellTiter One-Solution-Assay (Promega) and
reading absorbance at 490 nm.
GST pull-down assays
Expression vectors were transfected into U2OS cells using Lipo-
fectamine LTX, GST fusion proteins were induced, purified,
bound to Sepharose beads (GE Healthcare), and incubated with
U2OS whole cell extracts as described previously [16] in NETN
buffer (20 mM Tris/HCl (pH 8.0), 1 mM EDTA, 0.5 % Nonidet
P-40, 100 mM NaCl). After extensive washing, the samples were
separated on SDS/10 % polyacrylamide gels. Gels were blotted
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on to nitrocellulose and probed with antibodies. When compar-
ing interactions all GST-fusion proteins were diluted at similar
concentrations.
Antibodies and immunoblotting
The antibodies used were anti-Flag M2 (F1804, Sigma–Aldrich,
dilution 1:1000), anti-p53 (DO-1, sc-126, Santa Cruz Biotechno-
logy, dilution 1:1000), anti-MDM2 (SMP14, sc-965, Santa Cruz
Biotechnology, dilution 1:1000), anti-γ -tubulin (C-11, sc-17787,
Santa Cruz Biotechnology) and anti-β-actin (AC-15, sc-69879,
Santa Cruz Biotechnology, dilution 1:10000). Phospho-HEY1
(Ser-68) rabbit polyclonal antibody was generated using the phos-
phorylated peptide DRINN(pS68)LSELRRL-cys as immunogen
(Abyntek Biopharma S.L.). The antibodies were cross-adsorbed
with a non-phosphopeptide column to remove antibodies against
the non-phospho-specific epitope. Antibody specificity was veri-
fied by ELISA and DOT BLOT (Supplementary Figure S1).
Immunofluorescence analysis
U2OS grown on coverslips were transfected with 100 ng of the
plasmids indicated in the figure legends. After 24 h, cells were
fixed with 4 % paraformaldehyde in PBS for 15 min and per-
meabilized in 0.1 % Triton X-100 in PBS for 5 min. To perform
indirect immunofluorescence cells were incubated in 3 % BSA in
PBS for 30 min. Primary immunostaining with mouse anti-Flag
antibody (1:500) or mouse anti-γ -tubulin (1:100) was carried
out at RT for 1 h. Secondary immunostaining with Alexa Fluor
488 goat anti-mouse antibody (A11029, Life Technologies) was
performed at RT for 1 h. DNA was counterstained with DAPI.
Stained cells were mounted on glass slides and examined using
an Eclipse 90i microscope (Nikon).
Immunoprecipitation
U2OS cells, previously transfected with Flag-HEY1, were lysed
by incubation for 20 min at 4 ◦C, in NETN buffer (20 mM
Tris/HCl (pH 8.0), 1 mM EDTA, 0.5 % Nonidet P-40, 100 mM
NaCl). After centrifugation at 14 000 g for 15 min at 4 ◦C, the
supernatants were used for immunoprecipitation with anti-Flag
M2 magnetic beads (Sigma–Aldrich), previously washed four
times in the same NETN buffer, at 4 ◦C for 90 min. The immune
complexes with the magnetic beads were initially washed three
times with the NETN buffer. To perform liquid chromatography
coupled to tandem mass spectrometry the immune complexes
were washed five more times with the NETN buffer without
Nonidet P-40 and five times with 50 mM ammonium bicarbon-
ate. The magnetic beads were finally resuspended in ammonium
bicarbonate and subject to proteomic analysis.
Proteomic analysis by liquid chromatography
coupled to tandem mass spectrometry
Samples were digested by adding modified porcine trypsin (Pro-
mega) at a final ratio of 1:50 (trypsin–protein). Digestion pro-
ceeded overnight at 37 ◦C. After digestion, samples were vacuum-
dried and finally dissolved in 1 % acetic acid for liquid chro-
matography coupled to tandem mass spectrometry analysis as
described previously [17].
RESULTS
Simulation of HEY1 phosphorylation at residue S68
inhibits its ability to enhance p53 transcriptional
activity
To identify proteins that interact with HEY1, and possible post-
translational modifications that occur in those proteins, we trans-
fected Flag-tagged HEY1 expression vector into U2OS cells
and we performed immunoprecipitation with anti-Flag magnetic
beads. The immunocomplexes were analysed by using a proteo-
mic approach based on liquid chromatography coupled to tandem
mass spectrometry (LC–MS/MS). The present study identified
two serine residues phosphorylated in HEY1, Ser-68 and Ser-
246. Ser-68 is located in the middle of helix 1 within the HLH
domain, and is highly conserved between members of the bHLH-
O family and less closely related bHLH transcription factors such
as MYC and MAX (Figure 1). Ser-246 is located in a region of
HEY1 currently without known function and is only conserved
in the closely related HEY2 protein (Figure 1). Little is known
about the molecular mechanisms that regulate HEY1 function so
we investigated a possible regulatory role for those phosphoryla-
tion events in HEY1 biological activity. We generated HEY1
mutants in which Ser-68 or Ser-246 were replaced by aspartic
acid or alanine in an attempt to mimic or block their phosphoryla-
tion respectively. We tested the effects of those mutations in the
ability of HEY1 to stimulate transcription from p53-responsive
luciferase genes in transfected cells. Interestingly, the phospho-
mimetic substitution S68D almost completely abolished the abil-
ity of HEY to stimulate p53 transcriptional activity, whereas
the rest of mutations did not significantly affect HEY1 activity
(Figure 2A, Supplementary Figure S2). Western blot analysis
showed that the lack of function does not reflect lower protein
expression because HEY1-S68D steady-state protein levels are
higher than wild-type HEY1 (Figure 2B). This result reflects an
increase in HEY1 protein stability caused by the mutation S68D,
as demonstrated by comparing the levels of wild-type HEY1
and HEY1-S68D in U2OS cells after treatment with the protein
synthesis inhibitor cycloheximide (Figure 2B). Experiments per-
formed with MG-132, an inhibitor of proteasome and calpains,
suggested that HEY1 is degraded by the ubiquitin-proteasome
pathway ([18] and Figure 2C, top panel). Addition of the more
proteasome-specific inhibitor epoxomicin confirmed that HEY1
is mainly degraded by the proteasome (Figure 2C, bottom panel).
HEY1 is a nuclear protein, however nuclear exclusion of HEY1
has been observed in prostate cancer cells [10] and this alteration
prevents HEY1-dependent p53 activation [9]. To study whether
simulation of HEY1 phosphorylation at Ser-68 affects its cellular
localization we performed immunofluorescence analysis. Thus,
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Helix1 Helix2loop
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HEY2 60-
HEYL 55-
HES1 46-
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-93
-100
-105
-106
*
RRDRINNSLSELRRLVPSAFEKQGS--AKLEKAEILQMTVDHLKMLHT
RRDRINNSLSELRRLVPTAFEKQGS--AKLEKAEILQMTVDHLKMLQA
RRDRINSSLSELRRLVPTAFEKQGS--SKLEKAEVLQMTVDHLKMLHA
RRARINESLSQLKTLILDALKKDSSRHSKLEKADILEMTVKHLRNLQR
RRDHIKDSFHSLRDSVP---SLQG---EKASRAQILDKATEYIQYMRR
RRNELKRSFFALRDQIP---ELENN--EKAPKVVILKKATAYILSV--
SLGPVLP-VVTSASKLSPPL
SVAPCVPPLSTSLLSLSATV
SRGASSTRRARPLERPATPV
AAKVFGGFQVVPAPDGQFAF
MYC 366- -406
HEY1 236-
HEY2 245-
HEYL 239-
HES1 212- -231
-258
-264
-254
*
HEY1 S68
HEY1 S246
Figure 1 Schematic representation of HEY1
The asterisks indicate the two phosphorylated serine residues identified in the proteomic study (Ser-68 and Ser-246). The
helix–loop–helix domain of HEY1, HEY2, HEYL, HES1, MYC and MYC-associated factor (MAX), and the region around HEY1
Ser-246 and the equivalent serine in HEY2, HEYL and HES1 were aligned by ClustalW2 and formatted with BOXSHADE.
Identical amino acids are in black, and conserved residues are in grey.
we observed that none of the phosphorylation site mutants alter
the normal nuclear localization of HEY1 (Figure 2D).
Simulation of HEY1 phosphorylation at residue S68
specifically alters HEY1 protein–protein
interactions in vitro
HEY1 forms functional hetero and homo-dimers with other mem-
bers of the bHLH-O superfamily. The Ser-68 is located in the
Helix 1, within the HLH domain, the main determinant of the
homo- or hetero-dimerization surface between bHLH proteins
[19]. To address whether Ser-68 phosphorylation state affect
the interaction between HEY1 and other bHLH proteins, we
performed GST pull-down experiments. GST-wild-type-HEY1
and GST-HEY1-S68D interacted in a similar manner with HES1
(hairy and enhancer of split 1), however simulation of Ser-68
phosphorylation greatly reduced the ability of HEY1 to interact
with HEY2 (Figure 3A), suggesting that this phosphorylation
event modulates specifically HEY1 protein-protein interactions
with other bHLH-O proteins. HEY1 also interacts directly with
p53 in vitro [20] and the mutant HEY1-S68D showed reduced
ability to interact with p53 as compared with wild-type HEY1
(Figure 3B). The reduced interaction does not reflect lower GST-
HEY1-S68D expression because control Coomassie blue-stained
gels shown that it expresses at even higher levels than GST-wild-
type-HEY1 (Supplementary Figure S3), and the input of GST
fusion proteins used in the experiments were similar. Together,
these data indicate that the phosphorylation status of HEY1 Ser-
68 modulates specifically HEY1 protein–protein interactions.
HEY2 function is also regulated through
phosphorylation at the conserved serine in the
HLH domain
The conservation of a serine residue equivalent to HEY1 Ser-68
among all bHLH-O proteins suggests that its phosphorylation
could be a common regulatory mechanism. To investigate this
possibility we generated a HEY2-S67D phosphomimetic mutant
at the equivalent Ser-67 residue in HEY2. First we confirmed that
all three members of HEY family, HEY1, HEY2 and HEYL, are
able to stimulate p53 transcriptional activity in transient transfec-
tion experiments (Figure 4A, left panel). Subsequently, we com-
pared the p53-activating potential of wild-type HEY2 with the
mutant HEY2-S67D and we observed that simulation of HEY2
Ser-67 phosphorylation abolished its ability to stimulate p53 tran-
scriptional activity (Figure 4A, right panel). Moreover, in a sim-
ilar fashion than HEY1, the mutant HEY2-S67D protein is more
stable than wild-type HEY2 (Figure 4B). Hence, it appears that
this phosphorylation could be a general regulatory mechanism
for all members of the bHLH-O family.
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Figure 2 Simulation of HEY1 phosphorylation at residue Ser-68 inhibits its ability to enhance p53 transcriptional activity
(A) U2OS cells were transfected with 100 ng of PIG3-LUC and 200 ng of expression vectors for HEY1, HEY1-S68A,
HEY1-S68D, HEY1-S246A or HEY1-S246D. After transfection, cells were incubated 24 h. Subsequently cell lysates were
assayed using a dual luciferase reporter system. Normalized values are expressed relative to the activity of the reporter
in the absence of HEY1. The results shown represent the averages of results of three independent experiments assayed
in duplicate + S.D. (B) Simulation of HEY1 phosphorylation at residue S68 increases protein stability. U2OS cells
were transfected with expression vectors for Flag-tagged HEY1 or HEY1-S68D. Twenty-four hours after transfection cells
were treated with cycloheximide (CHX, 10 μg/ml) and HEY1 protein levels were analysed by western blotting at 0, 3
and 6 h after CHX addition. (C) HEY1 is degraded via proteasome. Degradation of HEY1 protein following cycloheximide
treatment was prevented by addition of different proteasome inhibitors; MG132 (25 μM) and Epoxomicin (Epox, 1 μM).
Anti-β -actin antibody was used as a loading control for all western blots. (D) Simulation of HEY1 phosphorylation does not
affect HEY1 nuclear localization. U2OS cells were transfected with expression vectors for Flag-tagged HEY1, HEY1-S68A
or HEY-S68D and assayed by indirect immunofluorescence with anti-Flag antibody. The first column shows the indirect
immunofluorescence with anti-Flag antibody, the second column shows DAPI staining of DNA and the third column shows
the merge image indicating the degree of colocalization. Bars, 20 μm.
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Figure 3 Simulation of HEY1 phosphorylation at residue Ser-68 specifically alters HEY1 protein–protein interactions
(A) Whole-cell extracts from U2OS cells previously transfected with expression vectors for Flag-tagged HES1 or HEY2
were incubated with GST fusion proteins of HEY1 or HEY1-S68D coupled with Sepharose beads. The associated proteins
were detected by western blotting using anti-Flag antibody. (B) Whole-cell extracts from U2OS cells previously transfected
with expression vector for p53 were incubated with GST fusion proteins of HEY1, the mutant HEY1-S68A, or HEY1-S68D
coupled with Sepharose beads. The associated proteins were detected by western blotting using anti-p53 antibody.
Simulation of HEY1 phosphorylation at residue S68
inhibits HEY1 ability to induce p53-dependent cell
cycle arrest
HEY1 expression induces p53-dependent growth arrest in
Ewing’s sarcoma family tumour cells [8] and we have pre-
viously shown that HEY1 expression induces p53-dependent
cell-cycle arrest and aberrant cell differentiation in human os-
teosarcoma U2OS cells [9]. To examine whether simulation
of Ser-68 phosphorylation affects HEY1 function we gener-
ated tetracycline-inducible pools of U2OS cells stably express-
ing either HEY1 (U2OS-HEY1) or HEY1-S68D (U2OS-S68D)
(Figure 5A). As expected, induction of wild-type HEY1 expres-
sion inhibited cell proliferation (Figure 5B). In contrast, induc-
tion of HEY1-S68D expression did not stop cell proliferation
(Figure 5B). HEY1 effects on cell proliferation are accompan-
ied by neuron-like differentiation, down-regulation of expression
of components of the Notch pathway and RUNX2, a master
regulator of osteoblast differentiation, and modulation of ex-
pression of several cell-cycle regulatory genes [9]. However,
expression of the phosphomimetic mutant HEY1-S68D failed
to reproduce these effects (Supplementary Figure S4). These
results suggest that HEY1 phosphorylation at residue Ser-68
could play an important role in the regulation of HEY1 functions
in vivo.
Expression of the phosphomimetic mutant
HEY1-S68D failed to sensitize U2OS cells to
p53-activating chemotherapeutic drugs
p53 plays a central role in the sensitivity to chemotherapy
[21] and we previously shown that expression of HEY1
confers sensitivity to p53-activating chemotherapeutic drugs
on U2OS cells [9]. To determine whether simulation of Ser-68
phosphorylation also modulates HEY1-dependent sensitization
to chemotherapeutic agents we performed cytotoxicity assays
using cisplatin and doxorubicin. As previously reported,
induction of HEY1 expression in U2OS-HEY1 cells res-
ulted in an increase in sensitivity to both drugs (Figures 6A
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Figure 4 Simulation of HEY2 phosphorylation at residue Ser-67
inhibits its ability to enhance p53 transcriptional activity
(A) U2OS cells were transfected with 100 ng of PIG3-LUC and 200 ng
of expression vectors for HEY1, HEY2 or HEYL (left panel) or expres-
sion vectors for HEY2 or HEY2-S67D (right panel). After transfection,
cells were incubated 24 h. Subsequently cell lysates were assayed us-
ing a dual luciferase reporter system. Normalized values are expressed
relative to the activity of the reporter in the absence of HEY1. The
results shown represent the averages of results of three independ-
ent experiments assayed in duplicate + S.D. (B) Simulation of HEY2
phosphorylation at residue Ser-67 increases protein stability. U2OS
cells were transfected with expression vectors for Flag-tagged HEY2 or
HEY2-S67D. Twenty-four hours after transfection cells were treated with
cycloheximide (CHX, 10 μg/ml) and HEY2 protein levels were analysed
by western blotting at 0, 3 and 6 h after CHX addition.
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Figure 5 Simulation of HEY1 phosphorylation at residue Ser-68
inhibits HEY1 ability to induce p53-dependent cell cycle arrest
(A) Immunoblot analysis of HEY1 expression in stable U2OS cell lines
expressing inducible HEY1 (U2OS-HEY1) or the phosphomimetic mutant
HEY1-S68D (U2OS-S68D) treated with 1 μg/ml tetracycline (Tet) for
4, 8 or 24 h. The protein levels of β -actin are shown as a loading
control. (B) U2OS-HEY1 cells (top panel) or U2OS-S68D cells (bottom
panel) were treated either with vehicle (Control) or 1 μg/ml tetracycline
(Tet). Cell proliferation was monitored at different time points by using
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) assay. The results shown represent the averages
of results of two independent experiments assayed in quadruplicate +−
S.D.
and 6B). However, induction of HEY1-S68D expression
in U2OS-S68D cells did not alter the sensitivity of U2OS cells
to any of the drugs (Figures 6A and 6B), in accordance with the
above describe failure of this mutant to activate p53-dependent
signalling. We extended our study to possible effects of HEY1
expression on cellular sensitivity to resveratrol, a naturally
occurring polyphenol that appears to have many anti-tumour
effects on different cancer cells [22] mediated, at least in part,
by activation of p53 [23]. Again, as in the case of cisplatin and
doxorubicin, we observed that expression of HEY1, but not of
the mutant HEY1-S68D, conferred sensitivity to resveratrol on
U2OS cells (Figure 6C). Thus, it seems that HEY1 expression
causes a general sensitization of U2OS cells to anticancer
drugs, an effect that might be regulated by HEY1 Ser-68
phosphorylation.
STK38 and STK38L kinases phosphorylate HEY1
in vitro
Among the proteins that co-immunoprecipitated with HEY1 in
our proteomic study there were only four serine/threonine kinases
(Supplementary Table S1) and, by far, the two closely re-
lated STK38 (serine/threonine kinase 38) and STK38L (ser-
ine/threonine kinase 38 like) kinases (also known as NDR1
and NDR2 respectively) were the most frequently represented
protein kinases. We confirmed that HEY1 was able to interact
in vitro with STK38 and STK38L by using immunoprecipita-
tion assays (Figure 7A). These observations prompted us to in-
vestigate whether these two kinases could phosphorylate HEY1
Ser-68. Both STK38 and STK38L kinases are potently activ-
ated upon treatment of intact cells with okadaic acid due to
the inhibition of protein phosphatase 2A [24]. We transfected
Flag-tagged STK38 and STK38L into U2OS cells and purified
the kinases from cells treated (activated kinases) or untreated
(inactive kinases) with okadaic acid. These kinases were then
used in an in vitro kinase assay using affinity purified Flag-
HEY1 or the nonphosphorylatable Flag-HEY1-S68A as a sub-
strate. To detect the possible phosphorylation of HEY1 by STK38
kinases we generated an antibody that detects phosphorylation
at Ser-68. Thus, we observed in western blot assays that both
STK38 and STK38L, when activated upon okadaic acid treat-
ment, were able to phosphorylate wild-type HEY1 at Ser-68
(Figure 7B).
HEY1 phosphorylated at Ser-68 localizes at the
centrosome of mitotic but not interphase
U2OS-HEY1 cells
HEY1 is a nuclear protein [25] and we observed that both HEY1
Ser-68 mutants (S68A and S68D), similar to wild-type HEY1,
maintained uniform nuclear expression (Figure 2D). To invest-
igate whether HEY1 phosphorylation at Ser-68 could occur
in vivo at discrete nuclear structures, the localization of HEY1
phosphorylated at Ser-68 was assessed by confocal indirect
immunofluorescence. U2OS-HEY1 cells were incubated with
tetracycline for 6 h to induce HEY1 expression. Cells were then
immunostained using the anti-phospho-Ser-68-specific antibody.
We found that HEY1 phosphorylated at Ser-68 accumulate in
two discrete spots observed only in mitotic cells (ascertained by
mitotic chromatin condensation), in a number and arrangement
of spots resembling that of centrosomes. Double immunofluores-
cence experiments using anti-phospho-Ser-68-specific antibody
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Figure 6 Expression of HEY1 but not HEY1-S68D leads to increased sensitivity to cisplatin, doxorubicin and resveratrol
U2OS-HEY1 cells (left panels) or U2OS-S68D cells (right panels) were treated with 1 μg/ml tetracycline (Tet) to induce
expression of HEY1 or HEY1-S68D or with vehicle (Control). After 8 h cells were cultured with varying concentrations of
cisplatin (A), doxorubicin (B) or resveratrol (C) for another 72 h in the presence and absence of tetracycline. Subsequently,
cell viability was assayed using an MTS-based assay. Data were plotted relative to the drug-free controls. The results
shown represent the averages of results of two independent experiments assayed in quadruplicate +− S.D.
in combination with antibody against the centrosomal marker
γ -tubulin showed that HEY1 phosphorylated at Ser-68 local-
izes at centrosomes during mitosis (Figure 8). A functional
relationship between HEY1 and the centrosome is reinforced
by the high ratio of centrosomal proteins, or centrosome-
associated proteins, that co-immunoprecipitated with HEY1 in
the proteomic study (47 out 278 total proteins, Supplement-
ary Table S2). Collectively, these observations suggest that
HEY1 could play a role in the regulation of centrosome
function and this functional interaction could be regulated
by HEY1 phosphorylation at Ser-68 in a cell cycle-dependent
manner.
HEY1 interacts with multiple ribosomal proteins
Gene Ontology analysis of the genes encoding the proteins iden-
tified in the proteomic study (performed using STRING Web re-
sources, [26]) showed that among the top most enriched groups
were genes encoding proteins involved in ribosome assembly
and/or function (Supplementary Table S3). During the last few
years, perturbation of ribosomal biogenesis has emerged as an
important p53-regulatory pathway [27], and our study revealed
that many ribosomal proteins potentially interact with HEY1
(Supplementary Table S4). Moreover, seven ribosomal proteins
directly involved in the regulation of p53 activity co-precipitated
with HEY1; RPS7, RPL23, RPL11, RPS20, RPS25, RPS14 and
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Figure 7 STK38 and STK38L kinases phosphorylate HEY1 in vitro
(A) In vitro interaction of STK38 kinases with HEY1. Whole-cell extracts from U2OS cells previously transfected with ex-
pression vectors for V5-tagged HEY1 were incubated with Flag-tagged-STK38 or STK38L coupled with anti-Flag magnetic
beads. The associated proteins were detected by western blotting using anti-V5 antibody. (B) HEY1 is phosphorylated
at serine 68 in vitro by okadaic acid-activated STK38 and STK38L kinases. U2OS cells expressing Flag-tagged STK38
or STK38L kinases were incubated for 1 h with vehicle or 1 μM okadaic acid. Flag-tagged kinases were then immuno-
precipitated and assayed for kinase activity using immunopurified FLAG-tagged wild-type HEY1 or the non-phosphorylatable
HEY1-S68A mutant as substrate. Phosphorylation of HEY1 was determined by western blotting with anti-phospho-S68
antibody. Western blotting with anti-Flag antibody shows the amount of Flag-HEY1, Flag-STK38 or Flag-STK38L present in
each assay.
pSer68 DAPI Mergeγ-tubulin
Figure 8 Confocal section of U2OS-HEY1 cells showing high concentration of HEY1 phosphorylated at Ser-68 in the
centrosomes of mitotic cells
U2OS-HEY1 cells were treated with 1 μg/ml tetracycline to induce expression of HEY1. After 6 h cells were fixed and
processed for double immunofluorescence staining using antibodies specific for HEY1-phospho-S68 and the centrosome
marker γ -tubulin. DAPI is used to counterstain the nucleus. Bars, 20 μm. Two representative confocal microscopy images
are shown.
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Figure 9 In vitro interaction of RPL11 with HEY1
Whole cell extracts from U2OS cells previously transfected with expression vector for Flag-tagged RPL11 were incubated
with GST fusion proteins of full-length HEY1 or deletion mutants (A) coupled with Sepharose beads. Bound proteins were
detected by western blotting using anti-Flag antibody (B).
RPS3 [27–30]. A GST pull-down assay demonstrated that at least
one of them, RPL11, interacts directly with HEY1 (Figure 9B).
Using various HEY1 deletion mutants fused to GST we mapped
the RPL11-interacting domain of HEY1 to a small N-terminal
region (amino acids 1–49) of previously unknown function
(Figure 9).
HEY1 and RPL11 cooperate to inhibit
MDM2-mediated p53 degradation
RPL11, like other ribosomal proteins, activates p53 by binding
to MDM2 and suppressing its E3 ubiquitin ligase activity in re-
sponse to ribosomal stress [31]. Thus, RPL11 expression protects
against MDM2-directed p53 degradation when co-transfected in
p53-null human lung adenocarcinoma H1299 cells (Figure 10A,
left panel). Remarkably, in a similar experiment, wild-type HEY1
expression, but not HEY1-S68D expression, was also able to pre-
vent MDM2-mediated p53 degradation (Figure 10A, right panel).
Expression of wild-type HEY1 also promotes MDM2 accumula-
tion, possibly through inhibition of MDM2 self-ubiquitination
and degradation, as previously shown for RPL11 ([31], Fig-
ure 10A). These results suggest that HEY1 activates p53 sig-
nalling, at least in part, through inhibition of MDM2 ubiquitin
ligase activity. Moreover, this previously unknown function of
HEY1 can be regulated by phosphorylation of Ser-68. Parallel ex-
periments performed in H1299 cells transfected with suboptimal
amounts of HEY1 and RPL11 expression plasmids allowed us to
observe that HEY1 and RPL11 cooperate in preventing MDM2-
mediated p53 degradation (Figure 10B). To further analyse the
cooperation between HEY1 and RPL11 in p53 activation we co-
transfected suboptimal amounts of HEY1 and RPL11 expression
plasmids, either independently or in combination, together with
the p53-dependent PIG3-LUC reporter. We observed a syner-
gistic activation of PIG3-LUC reporter activity (Figure 10C),
reinforcing the idea that both proteins may cooperate in the ac-
tivation of p53.
Many ribosomal proteins activate p53 by direct binding to
MDM2. To explore the possibility that HEY1 could also interact
with MDM2 we performed a pull-down interaction assay. This
showed that GST-HEY1 was able to interact weakly but spe-
cifically with MDM2 (Figure 10D). Interestingly, simulation of
HEY1 Ser-68 phosphorylation completely abolished this inter-
action. Furthermore, simulation of Ser-68 phosphorylation also
inhibits the in vitro interaction between RPL11 and HEY1 (Fig-
ure 10E). These results indicate that there is a direct correlation
between HEY1 ability to interact with RPL11 and MDM2 and
its p53-activating activity, and these functional interactions could
be regulated by HEY1 phosphorylation at Ser-68.
The physical interaction between HEY1 and MDM2 suggests
that HEY1 could be substrate of MDM2. Hence, we determ-
ined whether HEY1 is subjected to MDM2-mediated degrad-
ation. When co-transfected into U2OS cells, ectopic expres-
sion of MDM2 dramatically reduced the steady-state level of
wild-type HEY1, indicating that HEY1 might be targeted to
proteasome-mediated degradation by MDM2. Moreover, simu-
lation of HEY1 phosphorylation at residue S68 partially prevents
MDM2-mediated HEY1 degradation (Figure 10F), in keeping
with the idea that this phosphorylation event stabilizes HEY1
protein and reduces its ability to interact with MDM2. Nutlin-
3 is a selective antagonist of MDM2 that binds MDM2 in the
p53-binding pocket, thereby preventing the interaction between
MDM2 and p53 and causing p53 stabilization ([32], Figure 10G,
right panel). To investigate the possibility that HEY1 could also
interact with MDM2 through the same p53-binding region we co-
transfected MDM2 and HEY1 or p53 in the presence of Nutlin-
3 and we observed that the drug was unable to protect HEY1
from MDM2-dependent degradation (Figure 10G, left panel).
This result suggests that HEY1 would not compete with p53 for
the binding to the same MDM2 region.
Ribosomal stress causes HEY1 perinucleolar
localization
To further explore a possible role for HEY1 in the modulation
of p53 activation by ribosomal stress we studied the effects of
treatment with the ribosomal stress-inducing agent actinomycin
D on HEY1 total protein levels and cellular localization in U2OS
osteosarcoma cells. U2OS cells were transfected with HEY1
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Figure 10 Functional interaction between HEY1 and RPL11
(A) Wild-type HEY1, but not the mutant HEY1-S68D, prevents MDM2-mediated p53 degradation. H1229 cells were trans-
fected, where indicated, with expression vectors for p53 (10 ng), MDM2 (1 μg), RPL11 (1 μg), HEY1 (1 μg) or HEY1-S68D
(1 μg). Twenty-four hours after transfection cells were harvested for immunoblot analysis with the specified antibodies.
(B) RPL11 cooperates with HEY1 to prevent MDM2-mediated p53 degradation. H1229 cells were transfected, where
indicated, with expression vectors for p53 (10 ng), MDM2 (1 μg), RPL11 (0.5 μg) or HEY1 (0.5 μg). Twenty-four hours
after transfection cells were harvested for immunoblot analysis with the specified antibodies. (C) RPL11 cooperates syn-
ergistically with HEY1 to enhance p53 transcriptional activity. U2OS cells were transfected with 100 ng of PIG3-Luc in the
presence or absence of 100 ng of expression vector for HEY1, 50 ng of expression vector for RPL11 or both together.
After transfection, cells were incubated 24 h. Subsequently cell lysates were assayed using a dual luciferase reporter
system. Normalized values are expressed relative to the activity of the reporter in the absence of HEY1. The results
shown represent the averages of results of four independent experiments assayed in duplicate + S.D. (D) Simulation of
HEY1 phosphorylation at residue S68 inhibits its interaction with MDM2. Whole-cell extracts from U2OS cells previously
transfected with expression vector for MDM2 were incubated with GST fusion proteins of HEY1 or HEY1-S68D coupled with
Sepharose beads. The associated proteins were detected by western blotting using anti-MDM2 antibody. (E) Simulation of
HEY1 phosphorylation at residue S68 inhibits its interaction with RPL11. Whole-cell extracts from U2OS cells previously
transfected with expression vector for Flag-tagged RPL11 were incubated with GST fusion proteins of HEY1 or HEY1-S68D
coupled with Sepharose beads. The associated proteins were detected by western blotting using anti-Flag antibody. (F)
MDM2 decreases the level of ectopically expressed HEY1. U2OS cells were transfected with expression vectors for MDM2
(2 μg) and Flag-tagged HEY1 (2 μg) or HEY1-S68D (2 μg). Twenty-four hours after transfection cells were harvested for
immunoblot analysis with the specified antibodies. (G) Effects of Nutlin-3 on MDM2-mediated degradation of HEY1 or p53.
H1229 cells were transfected, where indicated, with expression vectors for HEY1 (1 μg), p53 (10 ng) and MDM2 (1 μg).
Eighteen hours after transfection cells were washed and incubated with vehicle or 10 μM Nutlin-3 for an additional 24 h.
Subsequently, cells were harvested for immunoblot analysis with the specified antibodies.
expression vector and subsequently they were treated with 5 nM
actinomycin D for 1 h, 3 h or 6 h. Western blot analysis showed
that total wild-type HEY1 protein levels did not significantly
change (Figure 11A). However, immunofluorescence analysis
revealed that ribosomal stress causes a radical redistribution of
HEY1 protein. In non-treated cells HEY1 presents uniform nuc-
lear localization, however, 6 h after actinomycin D treatment
HEY1 migrates towards the margin of the nucleoli (Figure 11B),
accumulating in small structures, so-called nucleolar caps [33],
formed by accumulation of nucleolar components during differ-
ent stages of cellular metabolic activity. Based on differences
in phase contrast light microscopy, two types of nucleolar caps
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Figure 11 Ribosomal stress induced by actinomycin D causes HEY1 perinucleolar localization
(A) U2OS cells previously transfected with expression vector for Flag-tagged HEY1 were treated with actinomycin D
(5 nM) for 1, 3 or 6 h. HEY1 total protein levels were analysed by western blotting using anti-Flag antibody. (B) U2OS
cells previously transfected with expression vectors for Flag-tagged HEY1, HEY1-S68D or HEY1-S68A were treated with
actinomycin D (5 nM) for 6 h and assayed by indirect immunofluorescence with anti-Flag antibody. The first column shows
the indirect immunofluorescence with anti-Flag antibody, the second column shows DAPI staining of DNA and the third
column shows the merge image indicating the degree of colocalization. Bars, 20 μm.
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have been described; dark nucleolar caps and light nucleolar
caps [34]. We observed that HEY1 is found in phase light nucle-
olar caps (Supplementary Figure S5). Parallel experiments per-
formed with HEY1 phosphorylation site mutants HEY1-S68A
and HEY1-S68D revealed that, upon actinomycin D treatment,
the non-phosphorylatable HEY1-S68A accumulated in the same
nucleolar caps where wild-type HEY1 is found (Figure 11B).
Strikingly, the mutant HEY1-S68D that simulates Ser-68 phos-
phorylation, which is defective for p53 activation and RPL11 in-
teraction, does not change its uniform nuclear localization upon
actinomycin D treatment (Figure 11B). These observations indic-
ate that HEY1 could have previously unknown biological func-
tions in the nucleolar stress pathway, and, again, these activities
might be modulated by HEY1 phosphorylation at Ser-68. In ac-
cordance with these observations, in addition to the ribosomal
proteins, 12 nucleolar proteins co-precipitated with HEY1 in our
proteomic assay (Supplementary Table S5), reinforcing the no-
tion about a potential role for HEY1 in the nucleolus during
ribosomal stress. We confirmed that at least one of the nucle-
olar proteins, Non-Pou Domain Containing, Octamer-Binding
(NONO), was able to interact with HEY1 in vitro by using a GST
pull-down assay. Interestingly, this interaction is inhibited by sim-
ulation of HEY1 phosphorylation at residue S68 (Supplementary
Figure S6), in keeping with the notion that this phosphorylation
modulates HEY1 function during ribosomal stress. In view of the
high conservation of the serine residue in the HLH domain of all
bHLH-O proteins we examined the possible effects of ribosomal
stress induced by actinomycin D in the subcellular distribution of
HES1 and HEY2, two related members of the bHLH transcrip-
tion family, also involved in the activation of the p53 pathway
([7], Figure 4A)). Thus, we observed that HES1 and HEY2 also
accumulate in nucleolar caps in response to actinomycin D treat-
ment (Supplementary Figure S7), suggesting that the bHLH-O
transcription factors could share nucleolar functions.
DISCUSSION
The p53 protein is a pleiotropic transcription factor that plays a
crucial role in tumour suppression by regulating cell-cycle pro-
gression, apoptosis, senescence, angiogenesis and maintenance
of genomic stability. The cellular responses to p53 activation
depend on the type of stimuli, the duration of the signal, the
cellular context and the cross-talk with other signal transduction
pathways including TGF-β [35], Notch [36] and pRB [37], al-
though the detailed molecular mechanisms responsible for the
integration of these pathways are far from being fully elucidated.
HEY1 could play a part in their cross-talk because activation
of those pathways induces HEY1 expression [2–4], which then
participates in the activation of p53. Also, we have observed that
HEY1 can physically interact directly with p53 [20]. Therefore,
alterations in HEY1 function and/or expression might contribute
to oncogenesis. Here, we have uncovered a novel mechanism
of regulation of HEY1 function and stability by phosphoryla-
tion at a conserved residue, Ser-68, located in the HLH domain.
This serine is highly conserved among bHLH proteins and its
phosphorylation could affect the ability of these proteins to form
homo-and heterodimers and/or bind to DNA through the HLH
domain. In keeping with this, our study revealed that simulation
of HEY1 Ser-68 phosphorylation disturbs its ability to form het-
erodimers with HEY2, but not with HES1. This alteration in the
binding specificity might represent an additional mechanism of
control of bHLH-O protein dimer function. In addition, HEY1 in-
teracts with the repressor complex Sin3 through its bHLH [38]),
thus, HEY1 Ser-68 phosphorylation could also modulate HEY1
recruitment of transcriptional corepressors.
Simulation of HEY1 Ser-68 phosphorylation inhibits both its
ability to enhance p53 transcriptional activity and its physical
interaction with p53. We had previously shown that HEY1 pro-
tein is excluded from the nucleus in most human prostate can-
cers analysed [10], an alteration that would eliminate an activ-
ation signal for p53 tumour suppressor action [9]. However, the
inability of HEY1-S68D phosphomimetic mutant to stimulate
p53-dependent transcription does not reflect HEY1 exclusion
from the nucleus, since the mutant retains nuclear localization.
Interestingly, detection of phosphorylation in vivo by immun-
ofluorescence with an anti-phosho-Ser-68-specific antibody re-
vealed that there is accumulation of HEY1 phosphorylated at
Ser-68 in the centrosome during mitosis, although we cannot
exclude the possibility that phosphorylation of HEY1 Ser-68
occurs in other nuclear compartments at levels below the affin-
ity range of our anti-phosho-Ser-68-specific antibody. Consist-
ent with the observed centrosome localization we found numer-
ous centrosome-associated proteins that co-immunoprecipitated
with HEY1 in the proteomic study including centriolar struc-
tural proteins such as tubulins, Filamin-A, actin and Vimentin
but also key regulators of pericentriolar material recruitment like
CEP192 (Centrosomal Protein 192 kDa). Cell cycle-dependent
accumulation of HEY1 phosphorylated at Ser-68 at centrosomes
suggests that HEY1 has previously unknown functions in this
organelle, that might be regulated via direct HEY1 phosphoryla-
tion. The pleiotropic functions of p53 as a cell cycle control
protein include the regulation of centrosome homoeostasis and
centrosome duplication (reviewed in [39]). Interestingly, just like
in the case of phosphorylated HEY1, in mitosis, p53 localizes
at the centrosomes in an ATM-dependent manner, where it has
been proposed that monitors mitotic spindle integrity [40–42].
HEY1 could contribute to the modulation of p53 function in the
centrosome although further studies will be required to investig-
ate the possible role of HEY1, and other members of the bHLH-O
family, in the centrosome. In this work we have identified two
serine/threonine protein kinases that co-immunoprecipitated with
HEY1 and can phosphorylate HEY1 Ser-68 in vitro, STK38 and
STK38L, that belong to a subfamily of the AGC group of ser-
ine/threonine kinases highly conserved from yeast to man. Both
kinases are part of an extended Hippo tumour suppressor pathway
but they have also Hippo-independent cell cycle related func-
tions (reviewed in [43]). Notably, although endogenous STK38
and STK38L are present in the nucleus and cytoplasm, a sub-
population of these kinases associates with centrosomes and is
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required for proper centrosome duplication [44]. Therefore, it is
not surprising that substrates of these kinases are also localized
in the centrosome. Our initial observations suggest that HEY1
could be a physiological substrate for STK38 kinases and open
up the possibility that modulation of the activity of HEY proteins
via direct phosphorylation may be one of the molecular mechan-
isms by which STK38 kinases exert their function. Centrosomes
have recently become important as platforms for the integration
of numerous signalling pathways (reviewed in [45,46]). Thus,
HEY1, a downstream effector for several key transduction path-
ways, could affect centrosome-dependent functions, including
cell cycle control, development and DNA damage response.
STK38 and STK38L promote cell cycle progression at dif-
ferent levels: increasing the activity of the proto-oncogene C-
Myc [43,47], decreasing the stability of the cyclin-Cdk inhib-
itor protein p21 by direct phosphorylation at Ser-146 [48] and
phosphorylating Heterochromatin protein 1α (HP1α) during mi-
tosis [49]. In addition, cyclin D1 promotes cell cycle progression
through enhancing STK38 kinase activity [50]. Since expression
of wild-type HEY1, but not HEY1-S68D, causes p53-dependent
cell cycle arrest in U2OS cells, inhibition of HEY1 ability to
activate p53 transcriptional activity via direct phosphorylation
at Ser-68 by STK38 kinases would integrate with the mitogenic
signalling pathways induced by STK38 and STK38L.
We previously showed that expression of HEY1 sensitizes
U2OS cells to p53-activating chemotherapeutic drugs, such us
doxorubicin and cisplatin [9]. Here, we demonstrate that HEY1
expression also increases the sensitivity of U2OS cells to res-
veratrol, a dietary polyphenol with potential chancer chemo-
preventive properties (reviewed in [22]). However, expression
of the mutant HEY1-S68D failed to increase cell sensitivity to
any of the anticancer drugs tested, reinforcing the relevance of
this regulatory phosphorylation event in the biological function
of HEY1. Future work will determine the possible contribution
of p53-dependent and p53-independent mechanisms on HEY1-
mediated sensitization to chemotherapeutic drugs.
It was initially proposed that HEY1 activates p53 through re-
pression of MDM2 transcription, however HEY1 failed to bind
to any identified potential binding sites in the MDM2 promoter
[7]. In addition, we have observed that HEY1 can interact dir-
ectly with p53 [20]. Taken together, these observations suggest
that there are mechanisms for the activation of p53 by HEY1
other than the transcriptional repression of MDM2. We found
that HEY1 may have a stabilizing effect on p53 protein by
binding to and inhibiting MDM2 E3 ubiquitin ligase activity,
in a similar manner than the nucleolar protein ARF (alternative
reading frame) or a number of ribosomal proteins that are re-
leased from the nucleolus in response to nucleolar stress. Our
proteomic analysis revealed that several ribosomal proteins co-
immunoprecipitate with HEY1, including seven of the ribosomal
proteins shown to activate p53 by inhibiting MDM2 function, one
of which is RPL11, an essential player during p53 induction in
response to ribosomal stress with increasing relevance in tumour
suppression [31,51,52]. We have confirmed that HEY1 interacts
directly with RPL11 and, moreover, that both proteins cooperate
in the inhibition of MDM2-mediated p53 degradation resulting in
a synergistic positive effect on p53 transcriptional activity. These
findings suggest that HEY1 could play a role in regulating p53 re-
sponse to perturbations in ribosome biogenesis. In addition to the
apparent inhibition of MDM2 activity caused by HEY1 expres-
sion, our results suggest that HEY1 could also be a physiological
substrate of MDM2 since MDM2 down-regulates HEY1 protein
levels. Interestingly, Nutlin-3 does not prevent MDM2-mediated
HEY1 degradation, suggesting that the p53-binding pocket is
not the main binding site for HEY1 and raising the possibility
that HEY1, p53 and MDM2 could form ternary complexes. The
elucidation of the intricate interplay between HEY1, MDM2,
ribosomal proteins and p53 will require the identifications of
the protein complexes formed in vivo and fine mapping of the
domains responsible for the protein–protein interactions. Simu-
lation of HEY1 Ser-68 phosphorylation prevents HEY1 interac-
tion with MDM2 and RPL11. In keeping with this, the phospho-
mimetic mutant HEY1-S68D cannot protect p53 from MDM2-
mediated degradation. The mutant HEY1-S68D also failed to
migrate to nucleolar caps in response to ribosomal stress, also
showing reduced interaction with the nucleolar protein NONO.
Therefore, this functional interaction between HEY1 and the
ribosomal protein-MDM2 axis seems to be regulated by its phos-
phorylation at Ser-68.
Taken together, our results suggest that signalling pathways
that modulate HEY1 phosphorylation at Ser-68 could impinge
on the activation of p53 tumour suppressor protein and also in-
fluence cellular sensitivity to chemotherapeutic drugs. Therefore,
it may be potentially relevant to screen for alterations in the nor-
mal HEY1 phosphorylation levels at Ser-68 in human tumour
samples. If an association between HEY1 phosphorylation status
and the cancer phenotype can be found, STK38, STK38L and
other serine/threonine kinases responsible for the phosphoryla-
tion of HEY1 at Ser-68 may represent novel attractive targets
for therapeutic intervention. An important challenge for the fu-
ture will therefore be the elucidation of the complex signalling
network that connects HEY1 and these p53-activating pathways.
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